New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 4, 2012
11:02 EDTALXNAlexion:Data show substantial improvement with Soliris in patients with STEC-HUS
Alexion Pharmaceuticals announced the presentation of 28-week data from all enrolled patients in a multi-center trial of eculizumab, Soliris, in patients who developed Shiga-toxin-producing E. coli hemolytic uremic syndrome, STEC-HUS, during an outbreak in Germany from May 2011 to July 2011. In the study, eculizumab therapy was associated with rapid and sustained clinical improvements in thrombotic microangiopathy, TMA, and systemic organ complications. The study met its primary endpoint of global assessment of efficacy at 8 weeks with 94% of patients achieving a complete or partial response in systemic TMA and vital organ involvement. Key secondary endpoints were also met with high clinical and statistical significance, including global assessment of efficacy at 28 weeks as well as improvement in hematologic, renal and neurologic functions. Preliminary findings from an exploratory post hoc, matched-control analysis of patients with severe STEC-HUS receiving eculizumab versus other patients who received current best supportive care during the German epidemic were also reported, and showed that eculizumab treatment was associated with consistently higher rates of renal and neurological function improvement at weeks 8 and 28.1
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2016
09:26 EDTALXNLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:02 EDTALXNAlexion resumed with an Outperform at Leerink
Subscribe for More Information
February 4, 2016
07:40 EDTALXNAlexion guidance conservative, says Oppenheimer
Subscribe for More Information
07:32 EDTALXNAlexion shares should be bought aggressively, says SunTrust
Subscribe for More Information
07:26 EDTALXNAlexion weakness a buying opportunity, says Brean Capital
Subscribe for More Information
February 3, 2016
09:19 EDTALXNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Boot Barn (BOOT), up 20.7%... Oclaro (OCLR), up 8.2%... Edwards Lifesciences (EW), up 5.8%... Natural Health (NHTC), up 5.7%... Viavi Solutions (VIAV), up 2.8%. ALSO HIGHER: Conatus (CNAT), up 18.8% after the FDA has granted Fast Track designation to the company's emricasan development program for the treatment of liver cirrhosis... Marvell Technology (MRVL), up 3.3% after Starboard Value disclosed a 6.7% activist stake in the company... Syngenta (SYT), up 2.9% after ChemChina offers to acquire the company in a transaction valued over $43B. DOWN AFTER EARNINGS: Navios Maritime Partners (NMM), down 33.5%... National-Oilwell Varco (NOV), down 7.9%... Chipotle (CMG), down 5.7%... Yahoo (YHOO), down 1.9%... Mondelez (MDLZ), down 4.4%... Illumina (ILMN), down 4.6%... Alexion Pharmaceuticals (ALXN), down 3.5%... Merck (MRK), down fractionally.
06:36 EDTALXNAlexion reports Q4 non-GAAP EPS $1.13, consensus $1.10
Subscribe for More Information
06:33 EDTALXNAlexion sees FY16 EPS $5.00-$5.20, consensus $5.53
Subscribe for More Information
February 2, 2016
14:32 EDTALXNNotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use